Hepatitis B Surface Antigen Test

Hepatitis B surface antigen, or HBsAg, is a protein found on the outer shell of the hepatitis B virus (HBV). When this protein shows up in the blood, it means the virus is present and actively infecting liver cells. Because it appears early in infection and stays detectable in chronic disease, HBsAg has become the single most important marker for diagnosing hepatitis B.

The biology of HBsAg is tied to both the virus and the immune system. The virus makes three related surface proteins (small, middle, and large) that help it enter cells and spread. The immune system recognizes these proteins, which is how hepatitis B vaccines work: by teaching the body to attack HBsAg before infection takes hold. However, HBV can mutate its surface proteins. These variants sometimes escape detection, causing “occult” infections where the virus is present but standard tests miss it. Variants can also reduce vaccine effectiveness, though this is uncommon.

Clinically, the amount of HBsAg in the blood tells us more than just whether infection exists. High levels usually indicate active viral replication, while steadily declining levels suggest the immune system or treatment is gaining control. Complete loss of HBsAg, called seroclearance, is considered a functional cure. Patients who clear HBsAg, either spontaneously or with medication, face a far lower risk of liver cancer, cirrhosis (scarring of the liver), and liver failure. Unfortunately, this outcome is rare and not always permanent, depending on the treatment used and patient factors.

HBsAg testing has a few caveats. People with weakened immune systems, such as those with HIV, may have lower test sensitivity. Rarely, mutations in the HBsAg gene interfere with detection. This is why physicians often combine HBsAg with other tests, such as hepatitis B surface antibody (anti-HBs) and hepatitis B core antibody (anti-HBc), to build a complete picture of infection status. Still, HBsAg remains the cornerstone for diagnosis, disease monitoring, and judging whether new antiviral therapies are working.